IMPACT FACTOR 5.863 an Open Access Journal by MDPI
The Future Direction of Radiopharmaceutical Development for Cancer Theranostics
Guest Editor: Message from the Guest Editor
Dr. Martina Benešová Dear Colleagues Research Group Molecular Biology of Systemic The journal Pharmaceuticals is planning to publish a Radiotherapy, Research Program Special Issue covering the topic “The Future Direction of Imaging and Radiooncology, German Cancer Research Center Radiopharmaceutical Development for Cancer (DKFZ), Im Neuenheimer Feld Theranostics”, and I am cordially inviting you to contribute 223, D-69120 Heidelberg, an article to this volume. Germany. [email protected] The purpose of this Special Issue is to host research and review papers on the development of novel radiopharmaceuticals and therapy strategies for cancer theranostics, which hold a great promise for improved Deadline for manuscript patients’ outcomes in the future. Areas of interest include, submissions: closed (31 January 2020) but are not limited to: Identification of new targets for cancer theranostics; Design of novel radiopharmaceuticals for cancer theranostics; Evaluation of non-standard radionuclides potentially suitable for cancer theranostics; Experimental targeted radionuclide therapy strategies; Prospective combination therapy with targeted radionuclide therapy involved.
mdpi.com/si/28102 SpeciaIslsue IMPACT FACTOR 5.863 an Open Access Journal by MDPI
Editor-in-Chief Message from the Editor-in-Chief
Dr. Jean Jacques Vanden Because of your expertise in the field of drug sciences, I Eynde kindly invite you to consider publishing your current work, Formerly head of the Department in the form of a research article or a review, in the open of Organic Chemistry (FS), University of Mons-UMONS, 7000 access electronic journal Pharmaceuticals. Mons, Belgium Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer- reviewed and a final decision is provided to authors within 4–6 weeks a er submission. Papers are published on the web immediately a er acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.
We hope to handle your contribution to Pharmaceuticals soon.
Author Benefits
Open Access:— free for readers, with article processing charges (APC) paid by authors or their institutions. High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and many other databases. Journal Rank: JCR - Q1 (Pharmacology & Pharmacy) / CiteScore - Q2 (Pharmaceutical Science)
Contact Us
Pharmaceuticals Tel: +41 61 683 77 34 mdpi.com/journal/pharmaceuticals MDPI, St. Alban-Anlage 66 Fax: +41 61 302 89 18 [email protected] 4052 Basel, Switzerland www.mdpi.com